Orforglipron licensed dose regimens
Licensed dose regimens
Reviewed by the BestHealingPeptides Editorial Team ·
Orforglipron is a licensed prescription only medicine in the UK (Foundayo), not a research compound, and this page does not provide a dosing recommendation. The table below summarises the licensed regimen set out in section 4.2 of the UK Summary of Product Characteristics on the emc for Foundayo film-coated tablets, which applies to both weight management and type 2 diabetes; the dose and titration for any individual are set by their prescriber, and the current product information should always be checked.
For full mechanistic context, study summaries, and safety information, see the main Orforglipron research profile.
Reported routes of administration
- Oral film-coated tablet (once daily; licensed route)
Reported half-life
Elimination half-life of approximately 29 to 49 hours, enabling once-daily administration (UK SmPC section 5.2). The maximum concentration is reached 4 to 8 hours after a dose, and steady-state exposure is achieved after approximately 1 week of once-daily dosing. Orforglipron is highly bound (99.9%) in human plasma (SmPC section 5.2).
See the dedicated half-life reference page for fuller pharmacokinetic context.
Licensed dose regimens
| Indication | Route | Regimen | Note |
|---|---|---|---|
| Weight management in adults (Foundayo, MHRA-licensed) | Oral, once daily | Start 0.8 mg once daily. After at least 30 days increase to 2.5 mg once daily; after at least 30 days on the current dose increase to 5.5 mg; the dose may then be increased to the next level (9 mg, 14.5 mg or 17.2 mg once daily) after at least 30 days on the current dose, based on treatment response and tolerability. Maximum 17.2 mg once daily | Foundayo SmPC section 4.2. More than one tablet a day should not be taken to achieve the effect of a higher dose. The maximum is 9 mg once daily with a strong CYP3A4 inhibitor or a clinical OATP1B inhibitor, and strong CYP3A4 inducers should be avoided. Not recommended in severe hepatic impairment; no dose adjustment for age, sex, race or ethnicity, body weight, renal function including end-stage renal disease, or mild or moderate hepatic impairment. Safety and efficacy under 18 years have not been established. |
| Type 2 diabetes in adults (Foundayo, MHRA-licensed) | Oral, once daily | Same schedule as above: start 0.8 mg once daily, with increases after at least 30 days on each dose, to a maximum of 17.2 mg once daily | Foundayo SmPC sections 4.2 and 4.5. When added to existing therapy with a sulfonylurea and/or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered, and blood glucose self-monitoring is necessary to adjust it. When added to existing metformin and/or SGLT2 inhibitor therapy, the current dose of metformin and/or the SGLT2 inhibitor can be continued. |
| Administration and missed doses (both indications) | Oral; swallow the film-coated tablet whole | Once daily at any time of day, without food or water restriction. Tablets should not be broken, crushed or chewed. If a dose is missed, resume dosing as soon as possible; more than one tablet should not be taken per day | Foundayo SmPC section 4.2. The SmPC section 5.2 reports no clinically relevant food effect on exposure. |
| Clinical-trial capsule doses (not the licensed tablets) | Oral hard capsules used in the Phase 3 trials | Weight-management trials (ATTAIN-1, ATTAIN-2): 6, 12 and 36 mg capsules. Type 2 diabetes trials: ACHIEVE-1, -2 and -5, 3, 12 and 36 mg capsules; ACHIEVE-3, 12 and 36 mg capsules. | Foundayo SmPC section 5.1 states that the clinical studies were conducted with hard capsules and that tablets and capsules are not substitutable on a mg-per-mg basis. Equal-effect pairs (tablet to capsule): 0.8 to 1 mg, 2.5 to 3 mg, 5.5 to 6 mg, 9 to 12 mg, 14.5 to 24 mg and 17.2 to 36 mg. |